| 16.65 -1.03 (-5.83%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 26.27 | 1-year : | 30.69 |
| Resists | First : | 22.5 | Second : | 26.27 |
| Pivot price | 11.82  |
|||
| Supports | First : | 13.87 | Second : | 8.55 |
| MAs | MA(5) : | 14.77 |
MA(20) : | 11.5 |
| MA(100) : | 9.48 |
MA(250) : | 8.93 |
|
| MACD | MACD : | 1.5 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 73 |
D(3) : | 83.5 |
| RSI | RSI(14): 73.4 |
|||
| 52-week | High : | 22.5 | Low : | 3.8 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ IGMS ] has closed below upper band by 3.3%. Bollinger Bands are 178.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 18.33 - 18.43 | 18.43 - 18.5 |
| Low: | 15.05 - 15.14 | 15.14 - 15.2 |
| Close: | 16.51 - 16.66 | 16.66 - 16.77 |
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Wed, 18 Sep 2024
IGM Biosciences: Waiting For Godot (NASDAQ:IGMS) - Seeking Alpha
Wed, 18 Sep 2024
IGM Biosciences (NASDAQ:IGMS) Stock Price Down 4.1% on Insider Selling - MarketBeat
Wed, 18 Sep 2024
IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains? - Yahoo Finance
Tue, 17 Sep 2024
IGM Biosciences CFO sells over $17k in company stock - Investing.com
Tue, 17 Sep 2024
IGM Biosciences CEO sells shares worth over $45,000 - Investing.com
Tue, 17 Sep 2024
IGM Biosciences executive sells over $17k in company stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 34 (M) |
| Held by Insiders | 1.177e+007 (%) |
| Held by Institutions | 34.7 (%) |
| Shares Short | 5,640 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.2637e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -4 % |
| Return on Assets (ttm) | 95.4 % |
| Return on Equity (ttm) | -36 % |
| Qtrly Rev. Growth | 2.91e+006 % |
| Gross Profit (p.s.) | 999.44 |
| Sales Per Share | -642.84 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -168 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 1.44 |
| Dividend | 0 |
| Forward Dividend | 5.54e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|